How Will The Alzheimer’s Disease Diagnostic Market Expand At A CAGR Of 10.5% Through 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Alzheimer’s Disease Diagnostic Market Today And What Is Its Future Size?
In recent times, the Alzheimer’s disease diagnostic market has experienced a significant surge. The market is projected to expand from $6.56 billion in 2024 to $7.26 billion in 2025, with a compound annual growth rate (CAGR) of 10.7%. This robust growth during historical periods can be linked to an increasing incidence of Alzheimer’s disease and dementia, heightened awareness about the need for prompt diagnosis for efficient management, advancements in imaging technologies like MRI and PET scans, escalated investment in R&D for neurodegenerative diseases, and backing from government initiatives and funding for Alzheimer’s research and diagnosis.
The market size for diagnosing Alzheimer’s disease is predicted to experience a significant acceleration in growth over the next few years, reaching $10.81 billion in 2029 with an annual compound growth rate of 10.5%. Factors contributing to this growth during the forecast period include the formulation of blood-based biomarkers for a less invasive diagnosis, an increase in the demand for personalized medicines and precision diagnostics, the incorporation of artificial intelligence and machine learning into early diagnostic tools, an expansion in the use of digital health technologies for remote monitoring and diagnosis, and growing healthcare infrastructure in emerging markets to enhance accessibility. Foreseen trends for this time frame are the development of multi-modal diagnostic techniques that utilize imaging, biomarkers, and cognitive tests, a greater emphasis on point-of-care diagnostic responses for expedited results, the creation of wearable technology that continuously monitors cognitive health, an increase in collaborations between biotech enterprises and research institutions creating innovative solutions, along with an expansion in direct-to-consumer genetic testing for Alzheimer’s risk evaluation.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp
What External And Internal Drivers Are Influencing The Alzheimer’s Disease Diagnostic Market?
The expected surge in chronic diseases is set to fuel the expansion of the Alzheimer’s disease diagnostic market. Chronic ailments are persistent health conditions that last for over three months. The escalation in chronic illnesses is influenced by numerous intertwined factors such as lifestyle habits, environmental impacts, genetic predispositions, and socioeconomic circumstances. The existence of chronic illnesses like cardiovascular issues, diabetes, and high blood pressure heightens the risk of developing Alzheimer’s disease (AD) and other forms of dementia. For instance, a report released by the American Heart Association Inc., a non-profit organization based in the US, in January 2022 suggested that brain disorders are projected to rise to 9.3 million in the US by 2060, a number that is currently on the rise. Moreover, one out of every six individuals globally is afflicted with a brain disease. The report forecasts that by 2021, brain disorders will affect 1 billion people worldwide. Consequently, the surge in chronic diseases will spur the growth of the Alzheimer’s disease diagnostic market.
How Is The Alzheimer’s Disease Diagnostic Market Categorized Across Applications And Types?
The alzheimer’s disease diagnosticmarket covered in this report is segmented –
1) By Type: Triage; Diagnosis; Screening
2) By Diagnostic Technique: Biomarkers; Imaging Techniques; Genetic Testing; Cognitive Assessment Tests
3) By End User: Clinics; Hospitals; Diagnostic Centers; Pharmaceutical Companies; Academic Research Center
Subsegments:
1) By Triage: Cognitive Testing; Imaging Techniques
2) By Diagnosis: Biomarker Testing; Neuroimaging
3) By Screening: Neuropsychological Testing; Genetic Testing
How Are Industry Trends Steering The Expansion Of The Alzheimer’s Disease Diagnostic Market?
Leading businesses in Alzheimer’s disease diagnostic market are focusing on the advancement of blood-based biomarker tests. These advancements are anticipated to streamline the diagnostics for Alzheimer’s disease, reducing dependency on invasive procedures, and enhancing prompt medical attention for patients. For example, Quanterix, a biotechnology research company based in the US, launched the LucentAD p-Tau 217 test in October 2023. This test is a biomarker for Alzheimer’s pathology which demonstrates clinical sensitivity and specificity in blood. Traditional methods for measuring cerebrospinal fluid (CSF) biomarkers have been through positron emission tomography (PET) or lumbar puncture. However, these methods are expensive, invasive, and not widely accessible. In contrast, the LucentAD p-Tau 217 test combines the ultra-sensitive SimoaÒ technology of Quanterix with the well-researched p-Tau 217 antibodies of J&J Innovative Medicine, leading to improved accuracy and a more straightforward process.
Who Are The Global Leaders Steering The Alzheimer’s Disease Diagnostic Market Forward?
Major companies operating in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., Treventis Corporation
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report
What Are The Emerging Regional Trends Driving The Alzheimer’s Disease Diagnostic Market?
North America was the largest region in the alzheimer’s disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21093&type=smp
Browse Through More Reports Similar to the Global Alzheimer’s Disease Diagnostic Market 2025, By The Business Research Company
Hematology Diagnostic Devices And Equipment Global Market Report 2025
Immunochemistry Diagnostic Devices And Equipment Global Market Report 2025
Cancer Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
